About: GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study
Creator	Landoni, Giovanni Zangrillo, Alberto De Cobelli, Francesco Aliberti, Teresa Angelillo, Piera Boffini, Nicola Campochiaro, Corrado Cavalli, Giulio Ciceri, Fabio Dagna, Lorenzo De Luca, Giacomo Della-Torre, Emanuel Farina, Nicola Mette, Francesca Paolini, John Rovere-Querini, Patrizia Ruggeri, Annalisa Scarpellini, Paolo Tentori, Stefano Tomelleri, Alessandro Trapnell, Bruce Tresoldi, Moreno
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: Mortality in patients with COVID-19 pneumonia and systemic hyperinflammation is high. We aimed to examine whether mavrilimumab, an anti-granulocyte–macrophage colony-stimulating factor receptor-α monoclonal antibody, added to standard management, improves clinical outcomes in patients with COVID-19 pneumonia and systemic hyperinflammation. METHODS: This single-centre prospective cohort study included patients aged 18 years or older who were admitted to San Raffaele Hospital (Milan, Italy) with severe COVID-19 pneumonia, hypoxia, and systemic hyperinflammation. Patients received a single intravenous dose (6 mg/kg) of mavrilimumab added to standard care given by the hospital at the time. The control group consisted of contemporaneous patients with similar baseline characteristics who received standard care at the same hospital. The main outcome was time to clinical improvement (defined as improvement of two or more points on the seven-point ordinal scale of clinical status). Other outcomes included proportion of patients achieving clinical improvement, survival, mechanical ventilation-free survival, and time to fever resolution. Adverse events were monitored daily. FINDINGS: Between March 17 and April 15, 2020, 13 non-mechanically ventilated patients (median age 57 years [IQR 52–58], 12 [92%] men) received mavrilimumab and 26 patients (median age 60 [IQR 53–67], 17 [65%] men) in the control group received standard care. During the 28-day follow-up, no patients in the mavrilimumab group died, and seven (27%) patients in the control group died (p=0·086). At day 28, all patients in the mavrilimumab group and 17 (65%) patients in the control group showed clinical improvement (p=0·030), with earlier improvement in the mavrilimumab than in the control group (mean time to improvement 8 days [IQR 5 to 11] vs 19 days [11 to >28], p=0·0001). By day 28, one (8%) patient in the mavrilimumab group progressed to mechanical ventilation compared with nine (35%) patients in the control group who progressed to mechanical ventilation or died (p=0·14). By day 14, fever resolved in ten (91%) of 11 febrile patients in the mavrilimumab group, compared with 11 (61%) of 18 febrile patients in the control group (p=0·18); fever resolution was faster in mavrilimumab recipients versus controls (median time to resolution 1 day [IQR 1 to 2] vs 7 days [3 to >14], p=0·0093). Mavrilimumab was well tolerated, with no infusion reactions. Three (12%) patients in the control group developed infectious complications. INTERPRETATION: Mavrilimumab treatment was associated with improved clinical outcomes compared with standard care in non-mechanically ventilated patients with severe COVID-19 pneumonia and systemic hyperinflammation. Treatment was well tolerated. Confirmation of efficacy requires controlled testing. FUNDING: IRCCS San Raffaele Scientific Institute.
has issue date	2020-06-16(xsd:dateTime)
bibo:doi	10.1016/s2665-9913(20)30170-3
bibo:pmid	32835256
has license	no-cc
sha1sum (hex)	20823febe0c252f840cf7c578a7ce3ef644fcf69
schema:url	https://doi.org/10.1016/s2665-9913%2820%2930170-3
resource representing a document's title	GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study
has PubMed Central identifier	PMC7430344
has PubMed identifier	32835256
schema:publication	Lancet Rheumatol
resource representing a document's body	covid:20823febe0c252f840cf7c578a7ce3ef644fcf69#body_text
is schema:about of	named entity 'CLINICAL OUTCOMES' named entity 'STANDARD' named entity 'COVID' named entity 'pneumonia' named entity 'COVID' named entity 'prospective cohort study' named entity 'azithromycin' named entity 'COVID' named entity 'GM-CSF' named entity 'GM-CSF' named entity 'isoform' named entity 'markers of disease' named entity 'Mavrilimumab' named entity 'Fisher's exact test' named entity 'mechanical ventilation' named entity 'oxygen saturation' named entity 'COVID-19' named entity 'CRP' named entity 'COVID-19' named entity 'inflammation' named entity 'autoantibodies' named entity 'tobacco smoking' named entity 'serum' named entity 'COVID-19 pandemic in Italy' named entity 'positive airway pressure' named entity 'ICU' named entity 'mavrilimumab' named entity 'lactate dehydrogenase' named entity 'placebo effect' named entity 'respiratory support' named entity 'idiopathic' named entity 'administered intravenously' named entity 'antibiotic treatment' named entity 'fever' named entity '28 days' named entity 'STAT5' named entity 'log-rank test' named entity 'ICU' named entity 'afebrile' named entity 'anti-inflammatory' named entity 'ClinicalTrials.gov' named entity 'mechanically ventilated' named entity 'serum' named entity 'hyperinflammation' named entity 'T-cell' named entity 'mortality rate' named entity 'prospective cohort study' named entity 'mavrilimumab' named entity 'CRP' named entity 'intensive care unit' named entity 'GM-CSF' named entity 'transcription' named entity 'Mavrilimumab' named entity 'SARS-CoV-2' named entity 'mavrilimumab' named entity 'non-invasive ventilation' named entity 'ordinal scale' named entity 'granulocytes' named entity 'macrophages' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software